...

Uzbekistan Pharma Registration: Guide for Indian API Exporters (2026)

As a regulatory affairs or export manager for an Indian pharmaceutical firm, the Uzbekistan pharmaceutical market should be part of your 2026 plan.

Central Asia’s largest pharmaceutical market is in Uzbekistan; analysts estimate that for the 12 months ending September 2025, it was worth approximately $2.14 billion.[1]

Approximately 90% of all sales made within the country are based on imported drugs.

uzbekistan pharmaceutical market guide
Infographic created with AI assistance and reviewed by Nilesh Mendpara

Tashkent is actively seeking Indian investment, and as of May 2026, 397 Indian-funded businesses[2] were operating in the country.

Since 2018, growth in the pharmaceutical industry in Uzbekistan has been averaging over 13.4% per year[1]; therefore, the opportunity exists.

Both of these statements should be viewed together, and this article will treat both of these statements as such.

The market has also been forced to raise the bar for entry because of both painful and legitimate reasons.

Today, to enter this market, you must have verified GMP; you need to conduct extensive testing; and you need to provide a full dossier – not just the paperwork.

This guide will help Indian API exporters and formulation makers understand how to navigate the Uzbekistan pharmaceutical registration as of 2026.

Why the Uzbek market is so important; how things changed after 2022-23; the six steps to complete the pharmaceutical registration process; the different types of documents needed and which routes can be taken; and finally, what makes a responsible supplier.

Why Uzbekistan Is Worth Entering

Central Asia’s largest, fastest-growing market

Uzbekistan is the largest market within the region. Retail pharmaceutical sales from October 2024 through September 2025 are projected to be approximately $2.14 billion, compared to approximately $0.888 billion for 2018.[1]

central asia’s largest fastest-growing market
Infographic created with AI assistance and reviewed by Nilesh Mendpara

This represents an average annual rate of increase of more than 13.4%[1] during the time frame.

Uzbekistan’s market size is currently 54%[1] greater than that of Kazakhstan in terms of monetary value, with sales increasing by more than 31% while Kazakhstan’s decreased by 2.7%.

The market is also very fragmented. The top three suppliers (by value) represent only approximately 9.9% of the total market[1], so there are many opportunities for new credible suppliers to enter this market. 

As well as the government providing financial support to the demand for pharmaceutical products in Uzbekistan, the State is also investing EUR 1.2 billion[1] into the development of the Tashkent Pharma Park (a Free Economic Zone cluster that includes manufacturing, research and development and logistics).

This briefly outlines the business case for entering the Uzbekistani pharmaceutical market; i.e., there is a great and rapidly expanding import-led demand for pharmaceuticals and strong visible evidence that the government is supporting this sector.

Deeply import-dependent – and courting India

The structural demand gap is caused by the dependence on imports.

Imports represent approximately 89 per cent of all drug sales in terms of value (an increase from 87 per cent in 2018); therefore, the ability to meet consumer needs relies heavily on foreign producers.

Domestic manufacturers primarily compete in the lower-priced market; however, there has been an increasing trend towards higher-priced imports and new product development.

The Uzbekistani government wants to use Indian capital and expertise. In 2025, a total of US 292.9 [2] million in Indian direct investment was achieved.

By March 2026, 397 Indian invested businesses existed in Uzbekistan, of which 311 were joint venture companies.

According to the Deputy Minister of Investment, Industry, and Trade, Uzbekistan may be able to offer enhanced subsidies and technology-transfer incentives to attract more investment.

Approximately US$262.7 million[1] is from foreign sources.

It appears that policymakers view the production of pharmaceuticals as a strategic area for development and are seeking to form partnerships with entities that can produce products that comply with global quality standards.

To learn more about the products that Actiza provides, please review its API offerings, finished products, and the Actiza Export Sourcing Guide.

Why the Quality Bar Is Now Higher

What happened

On December 21, 2022, Uzbekistan reported the death of children who had ingested Dok-1 Max Syrup.

A RAPS summary of the World Health Organisation (WHO) alert indicated that 21 children contracted [3] acute kidney injury from consuming Dok-1 Max Syrup; of these 21, 18 passed away.

why the quality bar is now higher
Infographic created with AI assistance and reviewed by Nilesh Mendpara

The syrup was produced in India by Marion Biotech and imported into Uzbekistan by Quramax Medical.

As a result, Uzbek officials placed a ban on all Marion Biotech products, and a Marion Biotech spokesperson stated that the company was sorry for the fatalities.

​In January of 2023, WHO issued a Medical Product [4] Alert stating that Dok-1 Max and Ambronol were substandard.

Laboratory testing confirmed that there were excessive levels of diethylene glycol and/or ethylene glycol present within these products; both are human-toxic contaminants that can be fatal.

As the investigation progressed, so too did the death toll.

On February 26th, 2024, the Tashkent City Court handed down sentences to 23 individuals in connection with the deaths of 68 children.[5]

Among those sentenced were former officials who were charged with regulating the import of prescription drugs and Quramax executives; some of whom were convicted of selling low-quality drugs, negligence and misuse of power.

Additionally, the court ordered that each family of the 68 children who lost their lives receive a monetary payment of $80,000 as compensation.[6]

Seven of the convicted were ordered to pay these payments. Each death represents a child and a family.

How it reset the market

The problem is a mutual error. A contaminated product left the manufacturing facility, but the regulatory system to identify the contamination did not.

As a result, India’s regulator revoked Marion Biotech’s manufacturing license and detained several of its staff members.

Beginning June 1, 2023, India is requiring all companies exporting cough syrups to obtain a certificate of analysis from a government lab.

The WHO is encouraging all manufacturers of liquid-dose products to test their excipients for diethylene and ethylene glycol before use.

Uzbekistan’s framework is now being updated with a Presidential Decree on August 19,[7] 2025; this update will help strengthen the Centre for Pharmaceutical Products Safety.

In addition to updating its framework, Cabinet Resolution No. 738 (November 24, 2025)[7] replaced the 2018 Registration Rules.

For any company exporting products to Uzbekistan, meeting the requirements of genuine GMP and solvent testing is what it takes to do business in the country.

What Getting It Wrong Now Costs

GMP is now actively verified, not just certified

Under the Uzbekistan Good Manufacturing Practice (GMP) regulations, a paper certificate alone will no longer be adequate.

Effective January 1, 2026, all domestic and international manufacturers must have a national GMP certificate in order to apply for product registration or renewal.

The registration dossier for international manufacturers should contain a GMP certificate and the report of the most recent inspection, and the official registration review period does not include any time used by the regulatory agency to verify GMP compliance.

The regulatory agency determines on an individual basis if and when it will conduct inspections at each manufacturing facility; therefore, you should contact your local agent regarding these matters.

Foreign facilities are not held to a lower standard than domestic facilities, as the same national GMP certificate requirement applies equally to both.

Comments about the regulatory reforms state that the purpose of the GMP requirement was to improve production quality to meet international standards.

Documentation and testing rigour

All of the following documentation must be provided for each site in your supply chain:

  • Validated GMP Certificate.

  • Last Inspection Report.

  • A WHO-format CPP.

  • A complete CTD/eCTD dossier containing Module 1, as required by the country.

  • Uzbek-language labels/instructions.

  • Demonstrable controls for both DEG and EG in the manufacturing process of liquid products, as well as the materials that make up those products (excipients), per WHO’s recommendations.

Incomplete or inconsistent file reviews may cause additional scrutiny, as well as delays in approval.

Resolution 738 provides 45 days for correcting problems identified during the first examination, and 90 days for addressing problems identified during the subsequent specialised examination.

These two periods are in addition to the regular review process; therefore, each problem identified extends the amount of time required to obtain final approval.

The trust dimension

Reputation is linked to the dossier. The reputation of Indian Pharma in Uzbekistan has been harmed due to the 2022-23 events; therefore, each exporter will be evaluated based on this.

Manufacturers can gain credibility by providing evidence of their quality, such as inspections, tests and transparent supply chains, rather than through advertising.

This is an appropriate criterion, and therefore, an inadequately documented submission can affect how subsequent submissions from the same company are viewed.

The Pharmaceutical Registration Pathway, Step by Step

Step 1 – Appoint a local representative / authorised applicant

Use a qualified local partner to serve as the applicant/importer. The authorized representative should have a college degree in either Pharmacy, Medicine, Chemistry, or Biology.

This person/company will handle all of the submission processes and interactions with the Center for Pharmaceutical Products Safety.

Select a partner that will also be able to assist in GMP verifications and provide Uzbek language translations; those are two areas that may take longer than others.

Step 2 – Confirm the route: standard registration or WLA reliance

Decide if you will use the standard procedure or are eligible to apply through the recognition route.

The recognition route, which was announced as being available starting in October of 2025, allows products that have been registered with a WHO-listed authority or at WHO maturity level 4 to be registered via this method.

Because using the recognition route has significant implications for both what type of documentation you are required to provide and how quickly your product is processed, it is important to verify your eligibility prior to developing a timeline.

the registration pathway step by step
Infographic created with AI assistance and reviewed by Nilesh Mendpara

Step 3 – Compile the CTD/eCTD dossier

The CTD/eCTD dossier is to be built according to the regulation in force since 26 February 2026: Module 1, as per national regulations, along with quality, non-clinical and clinical modules, including the CPP, GMP certificates and inspection reports for each site and Certificates of Analysis.

All documents obtained outside of Uzbekistan are required to be apostilled or legalised; the rules identify the CPP, the GMP certificate with its inspection report and the manufacturing license for foreign manufacturers.

Step 4 – Prepare Uzbek-language labelling and documentation

The Summary of Product Characteristics, Instructions for Use, and Labelling should be provided in Uzbek language, although Russian is very frequently used.

Language and labelling issues can often be easily avoided and do not have to result in delays.

Step 5 – Submit and expect GMP inspection and sample testing.

Submit your application and samples to the Center. You can expect your application to undergo laboratory testing, verification that you meet Good Manufacturing Practices (GMP), and, depending upon the type of product you are submitting, potentially have to conduct some level of local clinical study.

Generic products may require clinical trials that can last up to one year, which do not fall within the official review clock.

Step 6 – Expert evaluation, decision and registration

Upon receipt of your application, the Centre will assess it, then either grant you approval to register your product or deny you approval.

Once approved, the Registration Certificate will remain in effect for 5 years.

There are no refunds for the registration review fee in cases where registration is denied.

If you receive approval to sell your product, you are required to report all adverse reactions to the Centre and maintain saleability of your product in the marketplace for at least 3 years.

Plan your timeline realistically. The formal period for the standard process is 210 days, and for medicines it is 45 days for medical substances.

This does not include any additional time required for deficiency responses, clinical trial data review or GMP verification; therefore, the actual amount of time you spend on the application may exceed this estimate.

Documents and the Reliance Route

Uzbekistan drug registration requirements are based upon a limited number of documents which must be consistent with each other, and on selecting the proper registration method as soon as possible.

Tables 1 & 2 illustrate the core files and registration routes, respectively. Use these tables as a checklist for your registration process, and not as an alternative to the actual regulations.

Core documentation for state registration

DocumentPurposeWatch-out
CTD/eCTD dossier (Module 1 national + Modules 2–5)Full technical, quality, safety and efficacy submissionModule 1 must meet current (February 2026) national requirements
Certificate of Pharmaceutical Product (CPP, WHO format)Confirms registration/approval in the country of originApostilled or legalised for Uzbekistan
Legalised GMP certificate + last-inspection report (every site)Proves GMP for the whole manufacturing chainRequired for each site; apostilled or legalised
Certificate of Analysis + specificationsBatch quality and testing basisInclude DEG/EG control for relevant excipients and liquids
Uzbek-language SmPC, IFU and labellingRegulatory and patient-facing complianceCommon cause of avoidable delay
Local representative appointment + qualified applicantLegal applicant and importerApplicant’s representative must hold arelevant higher-education degree

Three major issues need to be considered.

Firstly, all documentation must present a consistent message; i.e., the CPP, GMP Certificate, Certificates of Analysis (COA) and Dossier Modules must refer to the same sites, specifications and product versions.

Secondly, documentation produced outside your home country will require an Apostille or Legalisation process that can take some time to organise.

Finally, the qualifications of the local representative must meet the legal requirements for appointment as opposed to being viewed as a “courtesy”; therefore, please confirm his/her qualifications before making an appointment.

Which route applies – and how much it helps

RouteWhen it appliesEffect
Standard national registrationProducts without a qualifying trusted-authority registrationFull dossier, testing and, where required, GMP verification
WLA recognition / reliance (reported since October 2025)Products registered by a WHO-Listed Authority or a Maturity Level 4 regulatorStreamlined evaluation; confirm eligibility and required proof
Exceptional import without registrationOrphan medicines; medicines for particularly dangerous or epidemic infections, at Ministry of Health requestNarrow and Ministry-driven; not a general route to market

A priority process is available for drugs that do not have an active equivalent on the market, as well as those that are designated “orphan” drugs, those that the Ministry of Health has requested to be given higher priority, and the initial generic equivalents of original products.

Therefore, you should verify if your products meet the criteria for a priority process.

When the recognition process alters the entity evaluating your product, the applicant is still required to provide a comprehensive and logically consistent application file.

Please contact the Centre to determine the specific documentation that the Centre considers acceptable evidence of previous approval.

Do not assume that each international approval receives equal consideration.

The reliance is contingent upon whether or not the product has been registered through an approved authority.

Additionally, the applicant must have met all applicable dossier requirements.

Exceptional import does not replace registration; it provides coverage for a small number of categories and is initiated by the Ministry.

Market Access and the Localization Shift

Registration lets you sell; market structure and policy direction decide how you should enter.

Two forces matter: heavy import dependence today and a deliberate push toward local production tomorrow.

FactorThe realityWhat it means for an exporter
Import dependence~87 – 90% of sales by value are importedLarge, accessible demand, but registration and quality are the gate
Localization policyIncentives in pharmaceutical free economic zones;20% of state procurement reserved for domestic productsLocal manufacturing or a joint venture may be advantaged in public tenders
Regional-hub ambitionUzbekistan courts Indian investment and technology transfer as a Central Asian supply hubConsider local presence or a joint venture for long-term, tender-exposed business
Channel mixPredominantly prescription; retail concentrated in Tashkent and larger citiesDistributor relationships and urban reach matter

The path of movement is clear. The domestic producer’s share of volume increased from 40% to 41.2%[1] with imports leading in terms of value.

Uzbek officials state that they can provide additional subsidies, technology transfers and improved approval processes to encourage Indian manufacturers to locate in Uzbekistan.

These are statements of intention, not official programs; therefore, verify the current status prior to creating a strategy based upon these statements.

market access and the localization shift
Infographic created with AI assistance and reviewed by Nilesh Mendpara

Demand is also moving to higher-priced products. While the percentage of low-cost products (less than 1perproduct) has been decreasing, the number of mid-priced products (1-5) and high-priced products (5-$10) have increased.

Quality-assured exporting companies will therefore find it advantageous to position themselves as reliable providers of high-quality products, instead of offering the lowest prices possible.

Upon registration, commercial obligations apply.

A registrant has to make sure that the product is available on the market for a minimum of 3 years following registration.

However, if the product is being produced by a domestic manufacturer for export purposes, then this requirement is waived.

It’s therefore important to select a representative and distributor who will be able to provide continued product availability and pharmacovigilance, rather than just filing.

Furthermore, the selection of the distributor will impact your ability to reach customers in Tashkent and other major cities.

On local production, the Deputy Minister pointed out industrial parks and joint ventures with local partners as methods of developing capacity and at the same time meeting quality requirements.

This model is well known to us; 311 of the 397 Indian invested companies[2] are joint ventures.

Thus, both technology transfer and joint venture models represent possible ways for us to pursue long-term business through tenders.

However, these models require capital, local partners and time, and will not provide a shortcut around registration.

A pure import strategy will work at this point. However, to help protect against future risks (such as tender-driven long-term demand), it is beneficial to have a presence locally or jointly with another company.

Also, obtaining an authority-recognised registration may allow you to import products into the country more quickly than if you were to wait until after you decided on having a local joint venture presence.

What a Responsible Exporter Brings

In contrast to what was mentioned above, the export destination Uzbekistan would like to find today is based on quality and not just price.

To put it simply, this means:

  • Verifiable WHO-GMP certification, or when appropriate, registration with reputable agencies that allow the use of reliance routes.

  • Excipient qualification, testing of DEG/EG in liquid/syrup formulations;

  • Complete, consistent CTD documentation;

  • Transparency of the complete manufacturing process; and

  • All applicable export testing requirements must be met.

The barriers to entry in India are consistent with those of other countries.

There are more than 262 FDA-approved facilities[8] (or similar) outside the U.S. that are reported by government-related agencies.

what a responsible exporter brings
Infographic created with AI assistance and reviewed by Nilesh Mendpara

There are also more than 1,400 WHO-GMP-approved facilities,[8] and India accounts for 57% of APIs listed on WHO’s pre-qualified list.[8]

These statistics represent the country’s overall pharmaceutical sector and do not necessarily apply to all facilities or suppliers.

All suppliers must provide documentation demonstrating their current compliance status.

When you have your initial meeting with a distributor/regulator, be prepared to share your most recent WHO-GMP certification, copies of your most recent inspection report, CoA with DEG/EG test results for any batches that were manufactured during the time frame of interest.

A supply chain diagram illustrating the flow of materials used in your manufacturing process (from raw material sources to final packaging).

You should be able to verify every claim made by your supplier.

It is preferable to admit to having “honest gaps” in your compliance records than to overstate your compliance capabilities since both distributors and regulators will ultimately discover both types of discrepancies.

Approval by a recognised authority is only relied upon if both the product and the applicant meet all of the applicable regulations.

The 2023 cough syrup export testing requirements[9] have added a layer of control for those products that are most problematic.

The lesson of 2022-23 is not that India can’t provide safe supplies to Uzbekistan.

The lesson is that if you want to be a safe supplier, you must have discipline, which should never be considered optional by an exporter.

What This Means for a Quality-Assured Supplier

Uzbekistan is a big, fast-growing, import-reliant country that has high expectations for quality.

Therefore, those suppliers that take their responsibilities of being compliant seriously will be rewarded.

Compliance is defined by having WHO-GMP status (verifiable), approval from a recognised authority when such approval exists, good quality controls such as testing for solvents and excipients, complete CTD documentation and transparency in the manufacturing process.

Actiza Pharma has reached the standards of an API Finished Formulation manufacturer in India.

We encourage you to review our certifications, APIs/Finished Formulations and documentation against the requirements above before committing.

For those considering Uzbekistan or Central Asia, please contact us for further discussion regarding quality requirements, documentation and partnering.

This article provides general information regarding Uzbekistan and is not meant to be considered as legal counsel.

However, since regulations can change, please verify all information with the Centre before submission.

In summary, our recommendation is to evaluate a potential supplier based upon the documents they provide first, and secondarily based upon what they state.

It is suggested that you provide your product list and intended registration process and then obtain the necessary documentation required by the Uzbek authority.

Frequently Asked Questions

Q1. Who regulates pharmaceutical registration in Uzbekistan?

Pharmaceutical product registration in Uzbekistan is done at the Centre for Pharmaceutical Product Safety, which is part of the Ministry of Health. This centre’s function was increased with a presidential decree in August 2025.

The centre evaluates dossiers, samples and tests, and determines whether a product can be registered or not. Foreign companies typically work with a local representative who is qualified to submit an application.

Q2. What documents does Uzbekistan require to register an imported medicine?

The following core documents are required: the CTD/eCTD dossier; a WHO format CPP; a GMP certificate and most recent inspection report; and the manufacturing license, which should be apostilled or legalised if issued outside of Uzbekistan.

In addition, you will require Certificates of Analysis, sample(s), Uzbek language labelling, and a qualified local representative. Please confirm the applicable checklist with the Centre before submission.

Q3. How long does drug registration take in Uzbekistan?

The time to complete the review of a product under the standard procedure is 210 calendar days, while the review of a medicinal product may take 45 calendar days for medical substances. The time taken to address deficiencies, conduct clinical trials and verify compliance with Good Manufacturing Practices (GMP) will not be included within the calculation of the total time required to complete the review.

Therefore, it can be expected that the actual time required to complete the review of a product will extend beyond the standard procedure. It is recommended that you consult specialist advisers regarding the establishment of a timeline that accurately reflects the level of completion of your dossier.

Q4. Does Uzbekistan require a GMP inspection of foreign manufacturers?

A GMP (Good Manufacturing Practice) certification will be required for all foreign manufacturers starting January 1, 2026. This certification can only be obtained through a national regulatory agency.

The length of time allowed for the review process includes any time that was used to verify compliance with GMP regulations. To determine if an on-site inspection of a particular manufacturing facility has been conducted, please consult your local representative.

Q5. Is Uzbekistan a safe market for Indian pharmaceutical exporters after 2022–23 cough-syrup deaths?

No one should guarantee that the market is “safe” due to the serious court findings and actual deaths. To export products in a responsible manner, exporters must comply with the existing regulations, including verifying their Good Manufacturing Practice (GMP) and testing for diethylene glycol/ethylene glycol (DEG/EG).

It provides complete documentation and working with a qualified local partner. There will continue to be regulatory risks; however, quality is the best way to address these risks.

Conclusion

Uzbekistan represents a real possibility: Central Asia’s biggest and most rapidly expanding pharmaceutical sector, heavily dependent upon imports and very receptive to Indian companies.

In addition, the country’s experience has led to an increased requirement for quality products; consequently, its regulatory framework has been modified to enforce this.

These two aspects are not at odds with each other for Indian exporters.

There is a straightforward route to obtaining Uzbekistan pharmaceutical registration: provide a comprehensive CTD dossier, verify the GMP status of all manufacturing sites, conduct unbiased testing, and work with a reliable local distributor.

Companies that comply with these requirements will be able to establish long-term business relationships in Uzbekistan and benefit from a government that actively seeks out partners.

To enter Uzbekistan effectively, companies must do so responsibly by prioritising patient safety, providing evidence of product quality, and adhering to regulatory guidelines.

A responsible entry begins with a question each export manager can readily respond to? Can we demonstrate through documentation that each lot produced conforms to our specified standards?

Actiza is happy to assist in discussing any issues related to assessing the pharmaceutical supply chain and regulatory environment in Uzbekistan, or other parts of Central Asia.

​

  1. https://timesca.com/uzbekistans-pharmaceutical-market-in-2025-rapid-growth-foreign-investment-and-localization/
  2. https://www.dailyexcelsior.com/uzbekistan-can-provide-more-incentives-to-indian-pharma-firms-aims-to-become-regional-hub-for-supply/
  3. https://www.raps.org/resource/asia-pacific-roundup-who-warns-on-contaminated-cou.html
  4. https://www.who.int/news/item/11-01-2023-medical-product-alert-n-1-2023-substandard-%28contaminated%29-liquid-dosage-medicines
  5. https://www.rferl.org/a/uzbekistan-indian-medicine-prison/32835897.html
  6. https://www.tribuneindia.com/news/diaspora/indian-among-23-sentenced-in-uzbekistan-over-contaminated-cough-syrup-deaths-594813/amp
  7. https://www.legal500.com/developments/thought-leadership/new-rules-of-state-registration-of-medicinal-products-and-medical-devices-in-the-republic-of-uzbekistan/
  8. https://etinsights.et-edge.com/is-indian-pharma-ready-to-take-up-a-global-role/amp/
  9. https://eastmojo.com/national/2023/05/26/mandatory-testing-of-cough-syrup-before-exports-dcgi-asks-labs-to-give-priority-to-such-samples/

About the Author

Nilesh Mendpara MD of ACTIZA PHARMA Profile Image
Nilesh Mendpara

Nilesh Mendpara is the Managing Director of Actiza Pharmaceutical PVT. LTD., based in Surat, Gujarat, India. With over 10 years of experience in the pharmaceutical industry, Nilesh is passionate about spreading pharmaceutical knowledge and staying ahead of industry trends. He holds a Master of Pharmacy (Distinction) and a Bachelor's in Pharmacy from Rajiv Gandhi University of Health Sciences. Under his leadership, Actiza Pharmaceutical aims to be the most trusted partner for pharmaceutical exports worldwide, ensuring the highest standards of quality and safety. Connect with Nilesh to explore opportunities in advancing global healthcare.

[Read more]
Request A Call Back

We are a 100% export-oriented company and do not engage in domestic sales within India.